Skip to main content
In stock|Radiopharmaceutical / Nuclear Medicine

Ibritumomab Tiuxetan (Y-90)

Oncology TypeBoth (Solid & Hematologic)
Drug Class / MechanismRadiotherapeutic / Radiodiagnostic Agent
No Image
Description

Ibritumomab Tiuxetan (Y-90) is classified as a Radiotherapeutic / Radiodiagnostic Agent, sourced for use within our Radiopharmaceutical / Nuclear Medicine portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryRadiopharmaceutical / Nuclear Medicine
Oncology TypeBoth (Solid & Hematologic)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3